Redx Pharma plc RXC004 Phase 1 data to be presented at ESMO 2021 (4874L)

TIDMREDX

RNS Number : 4874L

Redx Pharma plc

13 September 2021

REDX PHARMA PLC

("Redx" or "the Company")

RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

Alderley Park, 13 September 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that data from the Company's RXC004 Phase 1 monotherapy study will be presented at the forthcoming European Society for Medical Oncology (ESMO) Congress, 16-21 September 2021.

RXC004 is the Company's lead drug candidate and is a potent, orally active porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. Based on the safety profile observed in the Phase 1 study, Redx has selected the 2mg dose of RXC004 for its planned Phase 2 monotherapy, proof of concept clinical trials which are expected to start during the second half of 2021.

The presentation at the ESMO Congress 2021 will be made by the Study Principal Investigator, Dr Natalie Cook, Consultant Medical Oncologist at the Christie Hospital NHS Trust, Manchester, UK.

 
 Presentation No:       517MO 
 
   Authors:               N Cook, S Blagden, J Lopez, D Sarker, A Greystoke, 
                          N Harris, F Kasmi, A Naderi, G Nintos, A Ortego 
                          Franco, R Pihlak, R Shinde, L Goodwin, C Phillips, 
                          J Robertson, A Saunders, C Tilston, S Woodcock, 
                          R Plummer 
 Title:                 Phase 1 study of the Porcupine (PORCN) inhibitor 
                         RXC004 in patients with advanced solid tumours 
 
   Day/Date:              Monday 20 September 2021 
 
   Presentation Time:     17:50pm to 17:55pm (CET) 
 
   Session Channel:       Channel 3 
 
   Session Title:         Developmental therapeutics 
 
   Session Type:          Mini oral session 
 
   Session Time:          17:30pm to 18:30pm (CET)

Redx to host R&D Event

Presented data will be discussed by Medical Experts during Redx's online R&D Event to be held on Monday 11 October 2021 at 1:00pm BST / 8.00am EDT. The event will also cover the Company's pipeline beyond RXC004.

To register for the event, please email redxpharma@fticonsulting.com .

 
For further information, please contact: 
 
Redx Pharma Plc 
 UK Headquarters 
 Lisa Anson, Chief Executive Officer              T: +44 1625 469 
                                                              918 
Karl Hård, Head of Investor Relations 
US Office 
 Peter Collum, Chief Financial Officer 
SPARK Advisory Partners (Nominated Adviser)        T: +44 203 368 
                                                             3550 
Matt Davis/Adam Dawes 
 
WG Partners LLP (Joint Broker)                     T: +44 20 3705 
                                                             9330 
Claes Spång/Nigel Birks/David Wilson 
 
Panmure Gordon (UK) Limited (Joint Broker)         T: +44 20 7886 
                                                             2500 
Rupert Dearden/Freddy Crossley/Emma Earl 
 
 
FTI Consulting                                     T: +44 20 3727 
                                                             1000 
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and intends to initiate multiple Phase 2 studies in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and recently commenced a Phase 1 clinical study in June 2021 where headline results are expected in H1 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals.

To subscribe to RNS announcements from Redx, please visit: https://www.redxpharma.com/investor-centre/email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFLEEEEFSEEU

(END) Dow Jones Newswires

September 13, 2021 02:00 ET (06:00 GMT)

Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jun 2024 to Jul 2024